Drug Discovery

#Cell therapy #Clinical trials #Covid-19 #Drug development #Drug discovery #Drug targets #Stem cells #Therapeutics

Exploring iPSCs for individual and population health applications

Listen to this article on the DDW Podcast: Brad Hamilton, Founder and Chief Science Officer at GoodCell examines the potential of induced Pluripotent Stem Cells. Across the world, patients suffering from heart failure, donor organ rejection and many other life-altering illnesses are struggling to combat the symptoms of their… Read More

#Editor's Choice #Exclusive Content #News

Human liver
#Drug delivery #Drug discovery #Liver disease

FDA Fast Track designation for liver disease treatment

Calliditas Therapeutics has been granted Fast Track designation by the US Food and Drug Administration (FDA) for its NOX inhibitor candidate setanaxib for the treatment of patients with the chronic orphan liver disease primary biliary cholangitis (PBC). Setanaxib has previously been granted orphan drug designation for PBC in the US… Read More

#News #Trending News

#Biologics / Biotechnology #Biomedicine #Drug discovery #Imaging #PET technology #Radiochemistry

MDC relaunches Wolfson radiochemistry facility

Medicines Discovery Catapult (MDC) has relaunched radiochemistry at the Wolfson Molecular Imaging Centre (WMIC) at the University of Manchester, UK. The facility, which was closed in 2020, includes the multi-million pound ‘Cyclotron’, one of only a few in the UK. It will supply radio-chemicals to drug discovery biotechs and academics,… Read More

#News

#Biologics #Cancer research #Drug development #mRNA #R&D

What it means for drug discovery to partner with a CDMO

Following the announcement by Samsung Biologics that it planned to add mRNA vaccine drug substance manufacturing services to its offering, DDW’s Megan Thomas spoke to Seahee Kim about what this means for both business and drug development.   MT: As a CDMO, Samsung Biologics can offer both development and manufacturing… Read More

#Business & Investment #Cancer Research #Editor's Choice #Exclusive Content #News

#AI #AI / data analytics / healthtech / informatics #Clinical trials #Drug discovery

Insilico Medicine discovers preclinical candidate for kidney fibrosis using AI

Insilico Medicine has announced today that its AI-powered drug discovery platform has delivered a preclinical candidate for kidney fibrosis. The preclinical candidate has desirable pharmacological properties and pharmacokinetic profile and has demonstrated highly promising results in in-vitro and in-vivo preclinical studies. Insilico Medicine is working to advance this program to… Read More

#News

#Clinical trials #Drug development #Drug discovery #Infectious diseases #mRNA #Novel therapeutics #Oncology #Research

This week in drug discovery (2-6 August)

News round-up by DDW’s Megan Thomas for 2-6 August This week has seen results released, research continued, and clinical trial phases completed. DDW’s Megan Thomas has rounded up her top five stories showing promise in the drug discovery industry. Cardiac patients receiving nasal gel showed reduction of S. aureus… Read More

#News #Trending News

#Clinical trials #Comment #Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines

From the editor: Staying focused

The drug discovery sector is amazing, says Lu Rahman. And while we have witnessed that on a global scale throughout the pandemic, we should also recognise some of the equally-outstanding non-Covid related developments that have recently taken place. There is, in my opinion, no better industry to be part of at the… Read More

#Covid-19 #Editor's Choice #Exclusive Content #News #Opinion

#Assays #Biotherapeutics #C elegans #Drug development #Drug discovery #Therapeutics #Viosciences

Unlocking the microbiome as a target for drug discovery using C. elegans

David Weinkove, CEO Magnitude Biosciences, examines the untapped microbiome and its potential into helping unlock new therapies. Why the microbiome? The human microbiome is an important emerging field for drug discovery that harbours an array of life-changing medicines for patients. Whilst it is increasingly acknowledged that the human microbiome holds… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News

#Drug development #Infectious diseases #Life sciences #Precision medicine #Research

Cerba Research awarded NIH contract for lab services

Cerba Research has been awarded a five-year contract for Clinical Central Laboratory Services from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH). Findings from this research are said to be vital to NIAID’s efforts to advance vaccines, drugs, and diagnostic… Read More

#News

#Drug development #Immunology / Virology & Vaccines #mRNA #Therapeutics

Sanofi to acquire Translate Bio

Sanofi has acquired Translate Bio as part of its endeavour to accelerate the application of mRNA to develop therapeutics and vaccines. Under the agreement, Sanofi will acquire all outstanding shares for a total equity value of approximately $3.2 billion (on a fully diluted basis). “Translate Bio adds an mRNA technology… Read More

#News #Trending News

#Clinical trials #Covid-19 #Drug design #Drug development #Drug discovery

ACRO releases toolkit to help advance decentralised clinical trials

The Association of Clinical Research Organizations (ACRO) released its DCT Toolkit, which lays out a vision for how decentralised clinical trials (DCTs) can be planned and executed now and in the future. When Covid-19 hit in March 2020, clinical trial participants were cut off from in-person clinical research visits. CROs… Read More

#News

#Drug development #Drug discovery #Immuno-oncology #Infectious diseases #Neurodegenerative disorders

This week in drug discovery (26-29 July)

News round-up by DDW’s Megan Thomas for 26-19 July DDW’s Megan Thomas rounds up her top five stories this week which show how innovation in drug discovery is enhanced by collaboration, be it financial backing or through the combining of differing expertise to achieve a common goal. SARS-CoV-2 spike… Read More

#News #Trending News

#AI / data analytics / healthtech / informatics #Automation / robotics #Biopharmaceuticals #Covid-19 #CRISPR #Drug discovery #Immunology / Virology & Vaccines #Lab automation #Moderna #Molecular Biology #Pfizer #Sequencing

What has 2020 taught us about lab automation?

Listen to this article on the DDW Podcast: Dr Patrick Courtney (SiLA consortium), Burkhard Schaefer (SiLA consortium/ASTM AnIML) and Oliver Peter, Senior Director, Senior Group Leader Biology Technologies and Lead Discovery, Biology, Idorsia Pharmaceuticals, look at the importance of automation in the face of global disease. As we write… Read More

#Covid-19 #Exclusive Content #News